Hi Davey, If we could extrapolate on these results we are...

Hi Davey,
If we could extrapolate on these results we are leading the field I think.
In the STORM study, Keytruda is used in combination with Intravenous Cavatak – the first time CVA21 has been administered intravenously in the clinic.

• The patient group includes NSCLC and metastatic bladder cancer.
• Of the 13 bladder patients, there were 5 partial responders and 6 with stable disease (most patients still on the study).
• Of the 6 lung patients, there were 3 partial responders (including one patient who appears very close to a complete response) and one stable disease.

Whats your view.?
Aloha.